Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

Ryota Tamura, Toshihide Tanaka, Kentaro Ohara, Keisuke Miyake, Yukina Morimoto, Yohei Yamamoto, Ryuichi Kanai, Yasuharu Akasaki, Yuichi Murayama, Takashi Tamiya, Kazunari Yoshida, Hikaru Sasaki

研究成果: Article

1 引用 (Scopus)

抄録

Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, the efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 different settings: tumors of initial resection (naïve Bev group), tumors resected following Bev therapy (effective Bev group), and recurrent tumors after Bev therapy (refractory Bev group). The paired samples of the initial and post-Bev recurrent tumors from 9 patients were included. The expression of programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1), CD3, CD8, Foxp3, and CD163 was analyzed by immunohistochemistry. The PD-L1+ tumor cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P <.01 for each). The PD-1+ cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P <.01 for each). The amount of CD3+ and CD8+ T cell infiltration increased in the refractory Bev group compared with the naïve Bev group (CD3, P <.01; CD8, P =.06). Both Foxp3+ regulatory T cells and CD163+ tumor-associated macrophages significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (Foxp3, P <.01 for each; CD163, P <.01 for each). These findings were largely confirmed by comparing paired initial and post-Bev recurrent tumors. Bevacizumab restores the immunosupportive tumor microenvironment in glioblastomas, and this effect persists during long-term Bev therapy.

元の言語English
ジャーナルCancer Science
DOI
出版物ステータスAccepted/In press - 2018 1 1

Fingerprint

Tumor Microenvironment
Glioblastoma
Neoplasms
Bevacizumab
CD274 Antigen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

これを引用

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. / Tamura, Ryota; Tanaka, Toshihide; Ohara, Kentaro; Miyake, Keisuke; Morimoto, Yukina; Yamamoto, Yohei; Kanai, Ryuichi; Akasaki, Yasuharu; Murayama, Yuichi; Tamiya, Takashi; Yoshida, Kazunari; Sasaki, Hikaru.

:: Cancer Science, 01.01.2018.

研究成果: Article

Tamura, R, Tanaka, T, Ohara, K, Miyake, K, Morimoto, Y, Yamamoto, Y, Kanai, R, Akasaki, Y, Murayama, Y, Tamiya, T, Yoshida, K & Sasaki, H 2018, 'Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab', Cancer Science. https://doi.org/10.1111/cas.13889
Tamura, Ryota ; Tanaka, Toshihide ; Ohara, Kentaro ; Miyake, Keisuke ; Morimoto, Yukina ; Yamamoto, Yohei ; Kanai, Ryuichi ; Akasaki, Yasuharu ; Murayama, Yuichi ; Tamiya, Takashi ; Yoshida, Kazunari ; Sasaki, Hikaru. / Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. :: Cancer Science. 2018.
@article{23b178240259464d991a3ea62facaaf6,
title = "Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab",
abstract = "Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, the efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 different settings: tumors of initial resection (na{\"i}ve Bev group), tumors resected following Bev therapy (effective Bev group), and recurrent tumors after Bev therapy (refractory Bev group). The paired samples of the initial and post-Bev recurrent tumors from 9 patients were included. The expression of programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1), CD3, CD8, Foxp3, and CD163 was analyzed by immunohistochemistry. The PD-L1+ tumor cells significantly decreased in the effective or refractory Bev group compared with the na{\"i}ve Bev group (P <.01 for each). The PD-1+ cells significantly decreased in the effective or refractory Bev group compared with the na{\"i}ve Bev group (P <.01 for each). The amount of CD3+ and CD8+ T cell infiltration increased in the refractory Bev group compared with the na{\"i}ve Bev group (CD3, P <.01; CD8, P =.06). Both Foxp3+ regulatory T cells and CD163+ tumor-associated macrophages significantly decreased in the effective or refractory Bev group compared with the na{\"i}ve Bev group (Foxp3, P <.01 for each; CD163, P <.01 for each). These findings were largely confirmed by comparing paired initial and post-Bev recurrent tumors. Bevacizumab restores the immunosupportive tumor microenvironment in glioblastomas, and this effect persists during long-term Bev therapy.",
keywords = "bevacizumab, PD-1, PD-L1, TAM, Treg",
author = "Ryota Tamura and Toshihide Tanaka and Kentaro Ohara and Keisuke Miyake and Yukina Morimoto and Yohei Yamamoto and Ryuichi Kanai and Yasuharu Akasaki and Yuichi Murayama and Takashi Tamiya and Kazunari Yoshida and Hikaru Sasaki",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/cas.13889",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab

AU - Tamura, Ryota

AU - Tanaka, Toshihide

AU - Ohara, Kentaro

AU - Miyake, Keisuke

AU - Morimoto, Yukina

AU - Yamamoto, Yohei

AU - Kanai, Ryuichi

AU - Akasaki, Yasuharu

AU - Murayama, Yuichi

AU - Tamiya, Takashi

AU - Yoshida, Kazunari

AU - Sasaki, Hikaru

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, the efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 different settings: tumors of initial resection (naïve Bev group), tumors resected following Bev therapy (effective Bev group), and recurrent tumors after Bev therapy (refractory Bev group). The paired samples of the initial and post-Bev recurrent tumors from 9 patients were included. The expression of programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1), CD3, CD8, Foxp3, and CD163 was analyzed by immunohistochemistry. The PD-L1+ tumor cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P <.01 for each). The PD-1+ cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P <.01 for each). The amount of CD3+ and CD8+ T cell infiltration increased in the refractory Bev group compared with the naïve Bev group (CD3, P <.01; CD8, P =.06). Both Foxp3+ regulatory T cells and CD163+ tumor-associated macrophages significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (Foxp3, P <.01 for each; CD163, P <.01 for each). These findings were largely confirmed by comparing paired initial and post-Bev recurrent tumors. Bevacizumab restores the immunosupportive tumor microenvironment in glioblastomas, and this effect persists during long-term Bev therapy.

AB - Although vascular endothelial growth factor (VEGF) promotes the immunosuppressive microenvironment, the efficacy of bevacizumab (Bev) on tumor immunity has not been fully investigated. The present study used 47 glioblastoma tissues obtained at 3 different settings: tumors of initial resection (naïve Bev group), tumors resected following Bev therapy (effective Bev group), and recurrent tumors after Bev therapy (refractory Bev group). The paired samples of the initial and post-Bev recurrent tumors from 9 patients were included. The expression of programmed cell death-1 (PD-1)/PD ligand-1 (PD-L1), CD3, CD8, Foxp3, and CD163 was analyzed by immunohistochemistry. The PD-L1+ tumor cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P <.01 for each). The PD-1+ cells significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (P <.01 for each). The amount of CD3+ and CD8+ T cell infiltration increased in the refractory Bev group compared with the naïve Bev group (CD3, P <.01; CD8, P =.06). Both Foxp3+ regulatory T cells and CD163+ tumor-associated macrophages significantly decreased in the effective or refractory Bev group compared with the naïve Bev group (Foxp3, P <.01 for each; CD163, P <.01 for each). These findings were largely confirmed by comparing paired initial and post-Bev recurrent tumors. Bevacizumab restores the immunosupportive tumor microenvironment in glioblastomas, and this effect persists during long-term Bev therapy.

KW - bevacizumab

KW - PD-1

KW - PD-L1

KW - TAM

KW - Treg

UR - http://www.scopus.com/inward/record.url?scp=85058959972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058959972&partnerID=8YFLogxK

U2 - 10.1111/cas.13889

DO - 10.1111/cas.13889

M3 - Article

C2 - 30467920

AN - SCOPUS:85058959972

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -